Docgo INC 8-K filings

DocGo Inc. has received an additional 180-day extension until January 25, 2027, to regain compliance with Nasdaq's minimum bid price requirement, with options including a reverse stock split.

DocGo Inc. has extended its existing share repurchase program through December 31, 2026, maintaining the authorized repurchase amount of $26 million.

DocGo Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved a reverse stock split and ratified the appointment of its independent auditor.

DocGo Inc. announces changes to its Board of Directors, including the departure of Stephen K. Klasko, MD, and the appointment of Michael Burdiek as Independent Chair.

DocGo Inc. announced significant losses for 2025 due to migrant program wind-down, but raised its 2026 revenue and adjusted EBITDA guidance while initiating a strategic alternatives review.

DocGo Inc. received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

DocGo Inc. announced the extension of its $26 million share repurchase program until June 30, 2026, continuing its commitment to shareholder returns.

DocGo reports a significant revenue decline in Q3 2025 due to migrant program wind-down, alongside record core business volumes and a net loss.

DocGo Inc. has acquired SteadyMD, Inc. for an aggregate purchase price of up to $25 million, comprising an upfront cash payment and a contingent earn-out.

DocGo Inc. has acquired virtual care platform SteadyMD, Inc. for up to $25 million, significantly expanding its telehealth services across all 50 states.

DocGo Inc. reported a significant revenue decline and net loss in Q2 2025 due to the planned wind-down of migrant-related programs, while reiterating full-year guidance and highlighting growth in core services.

DocGo Inc. announced the results of its 2025 Annual Meeting of Stockholders, where directors were elected and the auditor ratified, but two significant corporate governance amendments regarding corporate opportunities and officer exculpation were not approved.

DocGo Inc. announced that its Board of Directors has approved an extension of its existing $26 million share repurchase program until December 31, 2025, signaling continued confidence in its stock.

DocGo reports a decline in Q1 revenue due to the wind-down of migrant-related programs and revises its full-year guidance to reflect uncertainty in the Government Population Health vertical.

DocGo reports full-year revenue of $616.6 million, a slight decrease from the previous year, and announces a shift in focus towards core mobile health services amidst the wind-down of migrant-related programs.

DocGo's Board of Directors has approved an extension of its share repurchase program, allowing the company to continue buying back up to $26 million in shares until June 30, 2025.

DocGo's Q3 2024 revenue decreased by 26% year-over-year due to the planned wind-down of migrant-related programs, but the company saw significant growth in other areas and increased its full-year cash flow guidance.

DocGo has appointed Dr. Stephen K. Klasko as the new independent Chair of its Board of Directors, effective October 1, 2024, replacing Steven Katz who will remain as a consultant.

DocGo reported a 31% increase in revenue and a 354% increase in net income for the second quarter of 2024, while also raising its cash flow from operations guidance.

DocGo Inc. held its 2024 Annual Meeting of Stockholders, electing two Class III directors and approving various proposals, including executive compensation and auditor ratification.

DocGo announced a profitable first quarter of 2024, highlighted by a significant increase in revenue and adjusted EBITDA, despite a revised full-year revenue guidance due to an accelerated wind-down of migrant-related services.

DocGo Inc. has reported a cybersecurity incident where unauthorized access led to the acquisition of protected health information from a limited number of healthcare records within its U.S. ambulance transportation business.

DocGo's subsidiary, Rapid Reliable Testing NY, LLC, has extended its contract with the New York City Department of Housing Preservation and Development to provide services to asylum seekers until December 31, 2024.

DocGo Inc. announces leadership changes, including the appointment of CEO Lee Bienstock to the Board and the departure of Stan Vashovsky as director and Chair, effective April 1, 2024.

DocGo reported record fourth-quarter and full-year 2023 results, with significant revenue growth and increased adjusted EBITDA, while also updating its 2024 revenue guidance to $720-$750 million and introducing adjusted EBITDA guidance of $80-$85 million.

DocGo has announced a new share repurchase program, authorizing up to $36 million in buybacks over six months, following an amendment to its credit agreement.

DocGo issued a press release to refute allegations made by a short seller, highlighting its financial performance, compliance practices, and growth trajectory.